Negrete_buela roger

Entrega de l’Abstract

Nom: ROGER Cognoms: NEGRETE BUELA Universitat on estudies: Universitat Autònoma de Barcelona (UAB) Títol de la recerca: The antinociceptive effects of JWH-015 in chronic
inflammatory pain are produced by the nitric oxide-cGMP-PKG-KATP pathway
activation mediated by opioids
Autor/s: Roger Negrete, Arnau Hervera, Sergi Leánez, Jesús M. Martín-Campos and
Olga Pol
Departament: Grup de Neurofarmacologia Molecular, Institut de Recerca de
l’Hospital de la Sta Creu i Sant Pau & Institut de Neurociències, Universitat Autònoma
de Barcelona
Universitat: Universitat Autònoma de Barcelona (UAB)
País: Espanya
Abstract (màxim 500 paraules):
Background: Cannabinoid 2 receptor (CB2R) agonists attenuate inflammatory pain but the precise
mechanism implicated in these effects is not completely elucidated. We investigated if the peripheral nitric oxide-cGMP-protein kinase G (PKG)-ATP-sensitive K+ (KATP) channels signaling pathway, triggered by the neuronal nitric oxide synthase (NOS1) and modulated by opioids, participates in the local antinociceptive effects produced by a CB2R agonist (JWH-015) during chronic inflammatory pain. Methodology: For this purpose, in wild type (WT) and NOS1 knockout (NOS1-KO) mice, at 10 days
after the subplantar administration of complete Freund’s adjuvant (CFA), we evaluated the antiallodynic and antihyperalgesic effects produced by the subplantar administration of JWH-015 and the reversion of their effects by the local co-administration with a CB2R (AM630), a peripheral opioid receptor (naloxone methiodide, NX-ME) or a CB1R (AM251) antagonist. The antinociceptive effects produced by a high dose of JWH-015 combined with different doses of selective L-guanylate cyclase (ODQ) or PKG (Rp-8-pCPT-cGMPs) inhibitors or a KATP channel blocker (glibenclamide) were also assessed. The expression of CB2R and NOS1 in the dorsal root ganglia of WT and NOS1-KO mice, with and without chronic peripheral inflammation, was also evaluated by using the real time PCR and western blot assays. The mechanical allodynia and thermal hyperalgesia induced by CFA were measured by using the von Frey filaments and plantar tests, respectively. Results: Our results show that the local administration of JWH-015 dose-dependently inhibited the
mechanical and thermal hypersensitivity induced by CFA which effects were completely reversed by the local co-administration of AM630 or NX-ME, but not AM251. The antinociceptive effects of JWH-015 were absent in NOS1-KO mice and significantly diminished by their co-administration with different doses of ODQ, Rp-8-pCPT-cGMPs or glibenclamide. Our data also demonstrate that chronic inflammatory pain increased the dorsal root ganglia expression of NOS1, but not of CB2R. Conclusions: These data indicate for first time the participation of the peripheral nitric oxide-cGMP-
PKG-KATP signaling pathway, activated by endogenous opioids, in the antinociceptive effects produced by a CB2R agonist during chronic inflammatory pain. Our results also indicate that the increased nitric oxide synthesized by NOS1 participates in the local antinociceptive effects produced by a CB2R agonist during chronic inflammatory pain. These findings suggest that the activation of the peripheral nitric oxide cGMP-PKG-KATP signaling pathway might be an interesting therapeutic target for the treatment of chronic inflammatory pain with cannabinoids. Authorship: The author has contributed in the design, performing of the experiments, the analyses of
Publication: Part of these results has been presented as a communication to the 16th World Congress on
Basic and Clinical Pharmacology, held in Copenhagen, Denmark, July 2010 and published in the Basic & Clinical Pharmacology & Toxicology, 107 (Suppl. 1), 162-692:487, 2010


Microsoft word - health2.doc

ISPS Health Standards and Benchmarks Grades 6-8 Standard 1 - Knows the availability and effective use of health resources in the community Benchmarks - By the end of Grade 8, students will: 1 – 1 Know the validity of common health products, services, and information 1 – 2 Know how to locate and use community health information, products, and services that provide va

National formulary grp1631 e.qxp:travelmedi pass_gb00200-e.qxd

Helping you make the most of your drug coverageYour group benefit plan covers drugs listed on the National Formulary. Although it covers approximately 85% of the mostfrequently prescribed drugs in Canada, you may find yourself with a prescription for a drug that isn’t on the list. This isimportant to understand because non-formulary drugs are either covered at a lower percentage, or not covered

Copyright ©2010-2018 Medical Science